ライフサイエンスコーパス: isosorbide dinitrate

1 63 for acetylcholine and r=-0.11, P=0.75 for isosorbide dinitrate).

2 t infusions of adenosine, acetylcholine, and isosorbide dinitrate.

3 y and sudden death compared with hydralazine/isosorbide dinitrate.

4 heart failure when given concomitantly with isosorbide dinitrate.

5 d by selective infusion of acetylcholine and isosorbide dinitrate.

6 Finally, an intracoronary bolus of isosorbide dinitrate (1000 microgram) was given.

7 n of hydralazine hydrochloride, 37.5 mg, and isosorbide dinitrate, 20 mg, for treating heart failure

8 not SV dilated in response to adenosine and isosorbide dinitrate (all P<0.05, RA versus SV, percent

9 Ivabradine and hydralazine/isosorbide dinitrate also have a role in the care of cer

10 of treatment with fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patien

11 Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced m

12 ing enzyme inhibitors and the combination of isosorbide dinitrate and hydralazine differs in black an

13 reported that the fixed-dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC

14 with greater impact of fixed combination of isosorbide dinitrate and hydralazine on the primary comp

15 We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional

16 ricle remodeling, outcomes and the impact of isosorbide dinitrate and hydralazine.

17 Isosorbide dinitrate and nitroglycerin markedly inhibite

18 ockers, aldosterone antagonists, hydralazine/isosorbide dinitrate, and anticoagulants.

19 03 for acetylcholine and r=-0.62, P=0.05 for isosorbide dinitrate) but not in LITA (r=-0.18, P=0.63 f

20 Although the combined use of hydralazine and isosorbide dinitrate confers important clinical benefits

21 In clinical trials, hydralazine-isosorbide dinitrate (H-ISDN) for heart failure with red

22 succinate, bisoprolol, carvedilol, digoxin, isosorbide dinitrate-hydralazine, spironolactone, and ep

23 Previous trials testing isosorbide dinitrate/hydralazine (I/H) were performed in

24 Fixed-dose combination of isosorbide dinitrate/hydralazine (ISDN/HYD) improved cli

25 and a fixed dose combination of hydralazine-isosorbide dinitrate in 2005.

26 ts in 24.1% (87.4% of eligible), hydralazine/isosorbide dinitrate in 8.6% (93.1% of eligible), and an

27 sion was also observed in vivo in rats given isosorbide dinitrate in the drinking water, with a dose-

28 overall effect of hydralazine hydrochloride-isosorbide dinitrate in the mostly white patient populat

29 ceived either 100 mg of sildenafil, 10 mg of isosorbide dinitrate (ISDN) or placebo during exercise o

30 creased overall mortality versus hydralazine/isosorbide dinitrate (p < 0.035) in V-HeFT II.

31 in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs.

32 randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addi

33 was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placeb

34 The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therap

35 r in combination with nitroglycerin (NTG) or isosorbide dinitrate restores Ca(2+) cycling and contrac

36 ethylenetriamine-NO and the organic nitrate, isosorbide dinitrate, the inhibitory effects of NO-aspir

37 combination of hydralazine hydrochloride and isosorbide dinitrate was approved by the U.S. Food and D

38 placebo therapy in V-HeFT I, and hydralazine/isosorbide dinitrate was compared with enalapril in V-He

39 on fraction >35%, treatment with hydralazine/isosorbide dinitrate was compared with prazosin and plac

40 w responses to adenosine, acetylcholine, and isosorbide dinitrate were comparable.

41 ions that compared hydralazine hydrochloride-isosorbide dinitrate with placebo or with enalapril.

42 t failure who took hydralazine hydrochloride-isosorbide dinitrate with standard therapy experienced a